EPA 2018 & 3 Things to Do While in Nice

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

Founded in 1983, the European Psychiatric Association is the number one association representing psychiatry in Europe. It has active individual members in 88 countries and 40 National Society/Association Members representing over 78000 European psychiatrists. EPA’s mission is to improve mental health care and psychiatry in Europe.

In 2018, EPA’s 26th European Congress of Psychiatry takes place in Nice between 3-6 March. The timetable and the programme are still work in progress. You can submit your proposal here. The congress promises to bring together expert clinical psychiatrists, researchers and leaders of stakeholder organizations in the field of mental health. The theme of the 26th edition will be Mental Health: Integrate, Innovate, Individualise.

 

Key Dates

  • Program Proposal Deadline: 10 May 2017
  • Abstract Submission Deadline: 26 Sept. 2017
  • Travel Grant Deadline: 26 Sept. 2017
  • Early Registration Deadline: 10 January 2018

Is EPA’s 26th European Congress of Psychiatry on your list in 2018? Give us a sign and we’ll handle your accommodation needs in a fast and reliable way!

 

Things to do while in Nice

Nice-France

Although Nice is the second-largest French city on the Mediterranean coast and the second-largest city in the Provence-Alpes-Côte d’Azur region after Marseille, the city is seen as the unofficial capital of the Côte d’Azur.

 

Enjoy a relaxing walk on Promenade des Anglais

The Promenade des Anglais is probably the most famous stretch of seafront in France, along the Mediterranean and extending from the airport on the west to the Quai des États-Unis on the east, over a distance of approximately 7 km. The promenade got its name from the English expat patrons who paid for it in 1822.

You can either choose to take a long walk and enjoy the sea breeze, rent skates, scooters and bikes from Roller Station or cruise along in an electric Segway from Mobilboard Nice.

Some of the promenade’s landmarks are the Hôtel Negresco, the art-deco Palais de la Méditerranée and Niçoise sculptor Sabine Géraudie’s giant iron sculpture La Chaise de SAB.

In 2015, the Promenade des Anglais was submitted as a candidate for the Unesco World Heritage status.

Connect with the past through art

Visit the Musée de Paléontologie Humaine de Terra Amata which was built on the site of a prehistoric settlement and where you can explore life on the Riviera 400,000 years ago through a variety of prehistoric artefacts.

You can also deep dive into the artistic movement and its history by admiring some 600 artworks at the Musée International d’Art Naïf Anatole Jakovsky. The building houses the Musée des Beaux-Arts, which is in itself a work of art and where you can gaze at pieces ranging from 15th century altar objects to Rodin’s imposing sculpture ‘The Kiss’. Artists represented include Chéret, Fragonard, Braque, Carrière, Chagall, Degas, Monet, Sisley, sculptures by Carpeaux and Rodin as well as pottery by Picasso. The museum also houses the Dufy painting collection and the Alexis and Gustav Adolf Mossa art collections.

 

Experience Nice to the fullest in the Old Town

The maze of narrow alleyways with restaurants, boutiques and bars give the picturesque Old Town of Nice a lively ambience reminiscent of Italy.

The layout hasn’t changed much over the past 3 centuries and the main piece is Cours Saleya, a huge market square that’s absolutely packed in summer. The food, flea and flower markets will delight your senses and make you fall in love with everything French.

A few steps away from the Cours Saleya is the Galerie des Ponchettes, a museum dedicated to the art work of Raoul Dufy. Also near the Cours Saleya is the Palais Lascaris, a Baroque palace from the 17th century that was the home of the Lascaris-Vintimille family, the Counts of Castellar.

Is EPA’s 26th European Congress of Psychiatry on your list in 2018? Give us a sign and we’ll handle your accommodation needs in a fast and reliable way!

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses, regardless of their location.

Advertisements

Deep Learning in Drug Discovery & Companies That Provide It

This article is brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

In order to better understand the meaning of deep learning, we first need to take a look at big data.

 

Big Data

New technologies such as the internet of things (IoT) and genomics generate huge data sets in a completely unstructured manner which are referred to as big data. These data sets are so large and so complex that they can’t be analysed using traditional apps and software. Therefore, new applications emerge. One of the biggest players in the field is Palantir Technologies, a company which helps make sense of all this big data. While storing this data is one thing, analyzing it is something completely different and it takes us to the concept of deep learning.

 

Deep Learning

Deep learning involves teaching a computer to make sense of all the unstructured big data using various methods like “artificial neural networks” which mimic the way the human brain works. What it does is use algorithms to search for complex relationships in all that “big data.”Those algorithms are constantly refined and improved.

Cognitive computing refers to a computer’s ability to learn more over time based on experience, much like the human brain does. You’ve probably read some articles on IBM’s Watson cognitive computing platform that uses deep learning for translation, speech-to-text, and text-to-speech. Deep learning or cognitive computing is a form of artificial intelligence.

Deep Learning & Drug Discovery

As explained so far, deep learning is a way to analyse big data and find relationships within huge data sets that would take years and years for humans to discover and process on their own.

If we see this in the context of the drug discovery industry, many years of research are needed to identify a drug compound that might be effective in combating a disease prior to seeking FDA approval. The FDA approval process is actually more like the cherry on top, it comes after huge research and extended trials. All this translates into billions spent by the pharmaceutical industry

on R&D with the aim of discovering compounds that treat specific diseases. Unfortunately, the path is long and rocky leading to only a fraction of all that research translated into commercial drugs.

Deep learning could make things faster and much more efficient by analysing a wide spectrum of already effective molecular compounds and use the findings to develop new drugs to combat diseases.

Some companies have turned to deep learning in an attempt to shorten the drug discovery cycle by building platforms that enable the discovery of new drug compounds, while predicting their likely success.

 

Atomwise

Founded in 2012, US-based deep learning company Atomwise is the creator of AtomNet, the first deep learning technology for novel small molecule discovery, characterized by its unprecedented speed, accuracy, and diversity. The company has worked with companies like Merck and has been involved in Ebola treatment research.

 

Insilico Medicine

Founded in 2014, Insilico Medicine raised USD 10M in a venture round in February 2017. The company is dedicated to finding novel solutions for cancer, aging and age-related diseases using advances in genomics and big data analysis. They provide services like advanced deep learning, custom drug and biomarkers discovery, aging research tools to academia, pharma and cosmetics companies.

 

Berg Health

Berg Health is a Boston-based biopharma company founded in 2006. They use their “Berg Interrogative Biology™ discovery platform” to reduce the time, and expense, of drug development. Berg focuses on three distinct areas: diagnostics, pharmaceutical research and development and health care analytics.

 

twoXAR

Founded in 2014, twoXAR is “an artificial intelligence-driven drug discovery company.” Using its computational platform, twoXAR identifies promising drug candidates, lowers risks through preclinical studies, and progresses drug candidates to the clinic through industry and investor partnerships. Their DUMA Drug Discovery platform evaluates enormous datasets to identify and rank high probability drug-disease matches in minutes rather than years.

Using deep learning for drug discovery is still in its early stages but it definitely shows great promise. By teaching a computer how to learn, relationships between vast data sets are uncovered thus helping scientists and researchers learn more about how to treat diseases whether they’re new or have been around for decades.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are:

Top Pharma News & Developments that Made Headlines in March

These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.

 

FDA approved Roche’s OCREVUS

roche

The US Food and Drug Administration (FDA) approved Roche’s OCREVUS (ocrelizumab) for relapsing and primary progressive forms of multiple sclerosis (MS).

OCREVUS reduced relapses per year by half during the two RMS Phase III studies. Furthermore, in a separate PPMS Phase III study, OCREVUS was the first and only treatment to significantly slow disability progression and reduce signs of disease activity in the brain compared with placebo with a median follow-up of three years.

The European Medicines Agency (EMA) has validated OCREVUS’ Marketing Authorisation Application (MAA) which is currently under review.

 

AstraZeneca Partnered with Circassia

astrazeneca-svg

AstraZeneca entered a strategic collaboration with respiratory biopharmaceutical company Circassia Pharmaceuticals plc. The agreement was signed for the development and commercialisation of inhaled respiratory medicines Tudorza and Duaklir in the US.

Tudorza and Duaklir are used for the treatment of chronic obstructive pulmonary disease (COPD). While Tudorza was launched in the US in 2012, Duaklir will be submitted for US regulatory review in 2018.

Under the agreement, AstraZeneca will receive a minority equity stake in Circassia while the latter will lead the promotion of Tudorza and was granted the rights to Duaklir in the US. AstraZeneca will complete ongoing development activities and continue to manufacture and supply both medicines.

 

MedImmune Formed Alliance with Sanofi Pasteur for MEDI8897

Impression

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have formed an alliance to develop and commercialise potential next-generation respiratory syncytial virus antibody MEDI8897.

The two companies will jointly develop and commercialise MEDI8897, a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV).

MedImmune and Sanofi Pasteur will equally share all costs and profits.

 

Mylan in Global Settlement & License Agreements with Genentech and Roche on Herceptin

Mylan_Logo

In March, Mylan has agreed to the terms of a global settlement with Genentech and Roche in what concerns patents for Herceptin (trastuzumab). This enables Mylan to have global licenses for its trastuzumab product.

Under the agreement, Mylan will be able to commercialize its trastuzumab product in markets worldwide. The licenses pertain to all countries except Japan, Brazil and Mexico.

As part of the settlement, Mylan agreed to withdraw its pending Inter Partes Review (IPR) challenges against two US Genentech patents (patent numbers 6,407,213 and 6,331,415).

 

Boehringer Ingelheim Expanded Its Collaboration with Vanderbilt University

boehringer_ingelheim_logo-svg

Boehringer Ingelheim has entered a collaboration with Vanderbilt University. This adds to an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS. This molecule activates KRAS and triggers a molecular switch that plays a key role when tackling some of the deadliest types of cancer.

This collaboration has led to discoveries that might set the scene for the development of novel cancer treatment options based on molecules that are able to block this critical cancer driver.

 

Merck’s Keytruda Got FDA Nod for Treating Blood Cancer

merck_logo

Merck got a first approval from the U.S. Food and Drug Administration (FDA) under the accelerated approval program for its immunotherapy drug Keytruda as a treatment for a type of blood cancer. Keytruda is already approved for treating lung, head and neck cancers.

FDA’s accelerated approval program allows for quicker approval of drugs that fill an unmet medical need.

cb-01

Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017, regardless of their location. The biggest congresses next year are: